Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 2.66
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness....
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of EDIT is 5.5 and suggests 110% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Data is available to registered users only
Buy
Sell